PRKAA2 and fatty liver disease: Hepatic AMPK activity has been identified as significantly associated with the prevalence of NAFLD, and activation of AMPK prevents NAFLD/NASH progression, including hepatic steatosis, fibrosis, and inflammation (33, 38).